FindTrial
Sign In

Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers

Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04424017
Enrollment
1546
Registered
2020-06-09
Start date
2020-06-07
Completion date
2020-10-30
Last updated
2021-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corona Virus Infection, COVID

Brief summary

The medical and paramedical staff of the front-line services are potentially exposed to SARS-CoV-2. Therefore, despite the application of standard protective measures, it is possible that a certain number of these personnel have already contracted SARS-CoV-2, including in its asymptomatic form. Serological testing in this context would be useful for deploying immune healthcare workers as to limit the risk of viral infection and transmission. Therefore, it is of utmost importance to prove that the serological response entails the production of neutralizing antibodies.

Interventions

BIOLOGICALSpecific anti-SARS-CoV-2 antibodies

A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples. All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA).

Sponsors

Cairo University
CollaboratorOTHER
National Research Centre, Egypt
CollaboratorOTHER
Academy of Scientific Research and Technology, Egypt
CollaboratorOTHER
Egyptian Center for Research and Regenerative Medicine
Lead SponsorOTHER_GOV

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Not previously diagnosed with COVID-19 except for convalescents * Not currently symptomatic with fever or respiratory symptoms (cough, dyspnea)

Exclusion criteria

* Patients with fever or respiratory symptoms (cough, dyspnea) * Refusal to give informed consent, or contraindication to venipuncture.

Design outcomes

Primary

MeasureTime frame
Describe the serological status of individuals in the study by presence of specific anti-SARS-CoV-2 antibodies3 Months

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026